Cargando…
The Association between Metabolic Syndrome and High-Stage Primary Urothelial Carcinoma of the Bladder
Recently, metabolic syndrome (MetS) has become an important public health problem, and its prevalence is increasing. MetS is associated with multifactorial diseases. No reports have suggested a relationship between bladder cancer and high blood pressure, and hyperlipidemia has been reported as a pos...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198774/ https://www.ncbi.nlm.nih.gov/pubmed/30374279 http://dx.doi.org/10.1159/000447229 |
_version_ | 1783365020547022848 |
---|---|
author | Nagase, Kei Tobu, Shohei Kusano, Shuhei Takahara, Kohei Udo, Kazuma Noguchi, Mitsuru |
author_facet | Nagase, Kei Tobu, Shohei Kusano, Shuhei Takahara, Kohei Udo, Kazuma Noguchi, Mitsuru |
author_sort | Nagase, Kei |
collection | PubMed |
description | Recently, metabolic syndrome (MetS) has become an important public health problem, and its prevalence is increasing. MetS is associated with multifactorial diseases. No reports have suggested a relationship between bladder cancer and high blood pressure, and hyperlipidemia has been reported as a possible risk factor. In the present study, we investigated the relationships between the stage and degree of malignancy of bladder cancer and MetS. Furthermore, we investigated the influence of the components of MetS on the results. We retrospectively analyzed the data of 169 patients who underwent transurethral resection of a bladder tumor in our department between Janurary 2005 and March 2011. MetS was significantly associated with a high histological grade (p < 0.05). MetS and low high-density lipo-protein were found to be significantly associated with the T stage; no other components of MetS were associated with a high stage or grade. Our results demonstrated that a lack of therapy for patients with low high-density lipoprotein levels could be riskier than was previously thought. |
format | Online Article Text |
id | pubmed-6198774 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-61987742018-10-29 The Association between Metabolic Syndrome and High-Stage Primary Urothelial Carcinoma of the Bladder Nagase, Kei Tobu, Shohei Kusano, Shuhei Takahara, Kohei Udo, Kazuma Noguchi, Mitsuru Curr Urol Original Paper Recently, metabolic syndrome (MetS) has become an important public health problem, and its prevalence is increasing. MetS is associated with multifactorial diseases. No reports have suggested a relationship between bladder cancer and high blood pressure, and hyperlipidemia has been reported as a possible risk factor. In the present study, we investigated the relationships between the stage and degree of malignancy of bladder cancer and MetS. Furthermore, we investigated the influence of the components of MetS on the results. We retrospectively analyzed the data of 169 patients who underwent transurethral resection of a bladder tumor in our department between Janurary 2005 and March 2011. MetS was significantly associated with a high histological grade (p < 0.05). MetS and low high-density lipo-protein were found to be significantly associated with the T stage; no other components of MetS were associated with a high stage or grade. Our results demonstrated that a lack of therapy for patients with low high-density lipoprotein levels could be riskier than was previously thought. S. Karger AG 2018-10 2018-06-30 /pmc/articles/PMC6198774/ /pubmed/30374279 http://dx.doi.org/10.1159/000447229 Text en Copyright © 2018 by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc-nd/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. |
spellingShingle | Original Paper Nagase, Kei Tobu, Shohei Kusano, Shuhei Takahara, Kohei Udo, Kazuma Noguchi, Mitsuru The Association between Metabolic Syndrome and High-Stage Primary Urothelial Carcinoma of the Bladder |
title | The Association between Metabolic Syndrome and High-Stage Primary Urothelial Carcinoma of the Bladder |
title_full | The Association between Metabolic Syndrome and High-Stage Primary Urothelial Carcinoma of the Bladder |
title_fullStr | The Association between Metabolic Syndrome and High-Stage Primary Urothelial Carcinoma of the Bladder |
title_full_unstemmed | The Association between Metabolic Syndrome and High-Stage Primary Urothelial Carcinoma of the Bladder |
title_short | The Association between Metabolic Syndrome and High-Stage Primary Urothelial Carcinoma of the Bladder |
title_sort | association between metabolic syndrome and high-stage primary urothelial carcinoma of the bladder |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198774/ https://www.ncbi.nlm.nih.gov/pubmed/30374279 http://dx.doi.org/10.1159/000447229 |
work_keys_str_mv | AT nagasekei theassociationbetweenmetabolicsyndromeandhighstageprimaryurothelialcarcinomaofthebladder AT tobushohei theassociationbetweenmetabolicsyndromeandhighstageprimaryurothelialcarcinomaofthebladder AT kusanoshuhei theassociationbetweenmetabolicsyndromeandhighstageprimaryurothelialcarcinomaofthebladder AT takaharakohei theassociationbetweenmetabolicsyndromeandhighstageprimaryurothelialcarcinomaofthebladder AT udokazuma theassociationbetweenmetabolicsyndromeandhighstageprimaryurothelialcarcinomaofthebladder AT noguchimitsuru theassociationbetweenmetabolicsyndromeandhighstageprimaryurothelialcarcinomaofthebladder AT nagasekei associationbetweenmetabolicsyndromeandhighstageprimaryurothelialcarcinomaofthebladder AT tobushohei associationbetweenmetabolicsyndromeandhighstageprimaryurothelialcarcinomaofthebladder AT kusanoshuhei associationbetweenmetabolicsyndromeandhighstageprimaryurothelialcarcinomaofthebladder AT takaharakohei associationbetweenmetabolicsyndromeandhighstageprimaryurothelialcarcinomaofthebladder AT udokazuma associationbetweenmetabolicsyndromeandhighstageprimaryurothelialcarcinomaofthebladder AT noguchimitsuru associationbetweenmetabolicsyndromeandhighstageprimaryurothelialcarcinomaofthebladder |